Friday, October 21, 2016
Medtronic Canada, a subsidiary of Medtronic plc (MDT), announced the Health Canada licence of its MiniMed™ 630G system with SmartGuard™ technology for people with diabetes mellitus. The MiniMed 630G system features a new insulin pump hardware platform and a new user-friendly design that combines personalized diabetes management with industry-leading clinical performance. The MiniMed 630G system is the newest offering of the MiniMed family-the #1 selling pump brand in Canada.
After interviewing more than 1,000 people with diabetes and testing user-experience, the enhanced features of the MiniMed 630G system were finalized to take into account what matters most to those with diabetes. This collaborative process with the patient community resulted in a new, user-friendly pump design that is waterproof and features a high-definition, full-colour screen that supports easy navigation and enables increased customization with more intuitive menus.
"We are excited to announce the launch of the MiniMed 630G system for Canadians living with diabetes. This latest innovation is a step towards Medtronic's vision of transforming diabetes care and our commitment to providing improved outcomes and an improved user experience for our customers," said Laura Cameron, Director of Diabetes & Consumer Care in Canada.
The MiniMed 630G system combines its proprietary SmartGuard technology with a brand new user-friendly design. The new pump platform fully integrates continuous glucose monitoring (CGM) and SmartGuard technology, which is designed to trigger an alarm when the CGM sensor glucose level reaches a preset low limit and suspends insulin delivery if the user is unresponsive to the alarm. SmartGuard technology is the only feature available in Canada that takes action against lows and is the only system proven to reduce the frequency of nighttime low episodes by a third.
Data from the ASPIRE In-Home Study published in the New England Journal of Medicine demonstrated that SmartGuard technology not only reduces the number of low events per week by 30 percent but also shortens the length/intensity of those events at night by 37.5 % without increasing A1C (a measure of average blood sugar levels over three months). These results were validated with real-world data from the company's CareLink™ Personal software that included an analysis of 581,822 days of data in Canada, which demonstrated SmartGuard technology users experience about half as many nighttime lows than those using a pump and sensor alone. MiniMed integrated insulin pump technology with CGM has also been proven to provide better glucose control than multiple daily injections without increasing hypoglycemia (low blood sugar).
The MiniMed 630G system with SmartGuard technology will be commercially available in Canada in early 2017.
Source : finance.yahoo.com
